Spots Global Cancer Trial Database for Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
Official Title: A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of MDV3100 (ASP9785) on the Pharmacokinetics of Substrates for CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in Patients With Castration-resistant Prostate Cancer
Study ID: NCT01911728
Study Description
Brief Summary: A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Parexel, George, , South Africa
Parexel/Qdot Pharma, Port Elizabeth, , South Africa
Contact Details
Name: Operation Senior Research Manager
Affiliation: Astellas Pharma Europe B.V.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
